Process-phase context
Authorized temperature, pressure or other unit-operation trends with batch and phase references. Compare equivalent phases and configurations rather than unrelated parts of a recipe.
SCOPED INPUT · HUMAN REVIEWRAIN / Pharma
Every process changeneeds its context.
A process trend depends on the unit operation, recipe phase, equipment state and the records behind it. A proposed RAIN evaluation would replay authorized historical data in a separate environment, testing whether contextual observations help process engineers investigate variability while quality teams retain control over records and changes.
Exploratory use case
INTELLIGENCE BELONGS WHERE THE DATA LIVES.
THE PHARMACEUTICAL MANUFACTURING QUESTION
Process context, evidence provenance and controlled model changes
THE INPUTS THAT MATTER
Read the right signals.
Choose a source to see the context it adds to this proposed review.
Source-record provenance
Source-system identity, timestamps, units and the metadata needed to interpret the approved extract. Preserve references back to the authoritative record.
SCOPED INPUT · HUMAN REVIEWEquipment and maintenance state
Equipment identity, calibration or service context and documented configuration changes. Use these to explain which periods belong in the same comparison.
SCOPED INPUT · HUMAN REVIEWApproved change context
Relevant process, method and model-version references, with evaluation configuration fixed for the replay. A changed recipe or model becomes a reviewable event.
SCOPED INPUT · HUMAN REVIEWAN OPERATING PATTERN WORTH EXPLORING
A slower heat-up, in the same process phase.
Proposed scenario: the quality and process teams approve a historical-data replay for one unit operation. The source manufacturing and quality systems remain authoritative and are not modified.
Pharmaceutical manufacturing / PILOT SCENARIO01 — REVIEW NOTES
Inspect the pattern.
The evaluation could compare heat-up duration across selected runs with matching recipe and equipment context, then identify the source intervals behind a difference. Incomplete or incomparable records would be labeled rather than scored as normal.
Bring it to the operator.
A process engineer checks the observation against original records, maintenance events and the approved process context. The quality team decides whether any formal investigation or change process applies.
Research proposal only. RAIN has no claimed GMP validation, regulatory approval or production integration. This scenario does not support batch release, a process-control decision or a compliance determination.
Pharmaceutical manufacturing / PROPOSED WORKFLOW
From operating context to review.
- 01
Define the intended study
Select one unit operation and a historical question. Have process and quality owners determine permitted data, study boundaries and what the output may be used for.
- 02
Preserve the evidence chain
Create an authorized replay dataset with source references and contextual metadata. Document exclusions and access permissions without changing the original records.
- 03
Freeze the evaluation configuration
Record the model, phase-mapping rules and comparison criteria before replay. Separate recipe or equipment changes into appropriate comparison groups.
- 04
Review findings against source records
Ask whether the proposed evidence adds useful context and can be reproduced. Quality owners determine how any finding enters existing investigation procedures.
- 05
Review before expanding the use
Treat a new model, data source or intended operational use as a separate scope decision. Historical usefulness does not establish production readiness.
WHAT A PILOT SHOULD PROVE
Define useful
before you measure it.
Suggested evaluation criteria. Set the baseline and acceptance thresholds with the sector team before a trial.
- 01Evidence traceability
- Share of sampled observations that can be reconstructed from the authorized source reference, input interval, model artifact and evaluation configuration.
- 02Repeatable replay
- Agreement of repeated evaluations using the same approved input snapshot, model version and configuration, within a tolerance established before the study.
- 03Review relevance
- Observations judged relevant by the process and quality reviewers divided by all reviewed observations. Preserve dismissed and inconclusive findings as evaluation evidence.
THE OPERATING BOUNDARY
Be precise about the scope.
The source record remains authoritative
The proposed study would not replace manufacturing records, audit trails or the quality-management system. A RAIN output or signed history is not itself evidence of regulatory compliance.
No autonomous model promotion in this proposal
Pin the model and configuration for the agreed evaluation. Further versions would require a separate documented review under the site’s applicable change process before being used.
No release or control authority
The scope excludes equipment actuation, batch disposition, specification changes and automated deviation closure. Applicability and validation decisions belong to the manufacturer’s qualified teams.
RESEARCH & CONTEXT
The thinking behind
this use case.
Primary sources reviewed September 2026. These explain the sector context; the scenario and pilot measures are RAIN proposals, not reported customer results or source endorsements.
- 01
U.S. Food and Drug Administration
Data Integrity and Compliance With Drug CGMP: Questions and AnswersFDA’s final guidance discusses reliable records, contextual metadata and reviewable audit trails. It informs source traceability and the separation between a study output and the authoritative manufacturing record.
- 02
U.S. Food and Drug Administration / ICH
Q10 Pharmaceutical Quality SystemICH Q10 describes quality-system oversight and the evaluation, approval and review of changes. The proposed study therefore fixes its model version and routes expansion through the manufacturer’s own review process.
- 03
U.S. Food and Drug Administration
Process Validation: General Principles and PracticesFDA frames process validation across a lifecycle and discusses ongoing evaluation of process variability. That context informs phase-aware comparisons; it does not validate RAIN or this proposed study.
03 / A FEW DETAILS
Worth understanding.
Can this support batch release today?
No. Batch release, quality disposition and process-control decisions are outside this exploratory scope. The current implementation does not establish suitability for those uses.
Does a signed history establish validation?
No. RAIN’s simulator records inference and model-change history. That implementation is evidence to inspect, not proof that a pharmaceutical application has been validated.
Pharma / EXPLORE THE FIT
Bring the question.
Define the study.
Start with the records, the review team, and the evidence a useful outcome would need. RAIN’s current implementation is a battery-storage simulator; this sector workflow requires its own validation.